Displaying drugs 10976 - 11000 of 12884 in total
Exbivirumab
Exbivirumab is an investigational monoclonal antibody. It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.
Investigational
Libivirumab
Libivirumab is an investigational monoclonal antibody. It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.
Investigational
Bos taurus colostrum immunoglobulins
Investigational
MCMV3068A
MCMV3068A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with MCMV5322A to form RG7667.
Investigational
Mazorelvimab
Investigational
Porgaviximab
Investigational
Cosfroviximab
Investigational
VAC-52150
Investigational
Cry5B
Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium Bacillus thuringiensis. With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal infections.[A259372, A259377]
Investigational
IMT504
IMT504, a non-CpG 24-mer oligodeoxynucleotide, is an immunomodulatory oligonucleotide currently being investigated as a rabies vaccine.
Investigational
CY 1899
Investigational
Miromavimab
Investigational
West Nile immune globulin
Investigational
LJP-538
Investigational
Lenvervimab
Investigational
ACP-015
Investigational
SIG-001
SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer modified alginate spheres.
Investigational
CUR-1916
Investigational
RST-001
RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channel rhodopsin-2 protein.
Investigational
GS030-DP
GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector. It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Investigational
WVE-N531
Investigational
OCU-100
Investigational
AAV1-FS344
AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor. It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752]
Investigational
MEDI-491
MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins.
Investigational
SPL23-2
SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.
Investigational
Displaying drugs 10976 - 11000 of 12884 in total